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Abstract
Patients withmetastatic ovarian cancer continue to have a dismal prognosis, emphasizing the need for new strategies
to identify and develop new molecular targets for therapy. Chemokine CXCL12 and its receptor CXCR4 are upregu-
lated in metastatic ovarian cancer cells and the intraperitoneal tumor microenvironment. CXCL12-CXCR4 signaling
promotes multiple steps in proliferation and dissemination of ovarian cancer cells, suggesting that targeted inhibition
of this pathway will limit tumor progression. To investigate CXCL12-CXCR4 signaling in ovarian cancer and establish
effects of inhibiting this pathway on tumor progression and survival, we designed a Gaussia luciferase complemen-
tation imaging reporter system to detect CXCL12 binding to CXCR4 in ovarian cancer cells. In cell-based assays, we
established that the complementation imaging reporter could detect CXCL12 binding to CXCR4 and quantify specific
inhibition of ligand-receptor interaction. We monitored CXCL12-CXCR4 binding and inhibition in a mouse xenograft
model of metastatic human ovarian cancer by imaging Gaussia luciferase complementation and assessed tumor pro-
gression with firefly luciferase. Bioluminescence imaging studies in living mice showed that treatment with
AMD3100, a clinically approved inhibitor of CXCL12-CXCR4, blocked ligand-receptor binding and reduced growth
of ovarian cancer cells. Treatment with AMD3100 also modestly improved overall survival of mice with metastatic
ovarian cancer. The Gaussia luciferase complementation imaging reporter system will facilitate further preclinical
development and optimization of CXCL12-CXCR4 targeted compounds for treatment of ovarian cancer. Our research
supports clinical translation of existing CXCR4 inhibitors for molecular therapy for ovarian cancer.
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Introduction
Ovarian cancer is the fifth leading cause of cancer death in women.
Survival remains poor, with overall 5-year survival rates of≈40% to
50% because patients with ovarian cancer typically are not diagnosed
until malignant cells have metastasized throughout the peritoneal
space into the abdomen and pelvis. Although up to 70% of patients
respond initially to debulking surgery and chemotherapy with platinum-
and taxane-based drugs, cancer recurs in most patients [1]. These facts
underscore ongoing efforts to identify new therapeutic targets and
strategies to improve treatment outcomes for patients with ovarian
cancer [2–5].
Recent studies indicate that chemokine CXCL12 (also known as
stromal-derived factor 1) and its receptor CXCR4 may drive progression
of ovarian cancer, making these molecules highly promising targets for
therapy [1,6]. Whereas normal ovaries express either no or minimally
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detectable CXCR4, this receptor is expressed by ovarian cancer cells in
≈60% of patients [7]. Expression of CXCR4 on ovarian cancer cells is
an independent prognostic factor for worse progression-free and overall
survival relative to patients without detectable CXCR4 on malignant
cells [7]. CXCL12 is expressed by more than 90% of ovarian cancer
cells and carcinoma-associated mesothelial cells, resulting in elevated
levels of this chemokine in ascites of patients with ovarian cancer [8–
10]. CXCL12 signaling through CXCR4 activates pathways that en-
hance proliferation, migration, and invasion of ovarian cancer cells
[8,11,12]. CXCL12-CXCR4 signaling also increases tumor angiogenesis
through effects on endothelial cells and recruitment of circulating
endothelial progenitor cells [13–15]. Collectively, signaling pathways
mediated by CXCL12-CXCR4 activate multiple processes that con-
tribute to growth and metastasis of ovarian cancer cells.
A key challenge in successfully targeting CXCL12-CXCR4 and other
molecules in ovarian cancer is determining the pharmacodynamics of
a compound in the tumor microenvironment. Even in preclinical mod-
els, effects of a chemotherapeutic agent on a specific molecule or path-
way typically are inferred by studies of surrogate tissues, such as blood
cells, or histologic analysis of excised tumors at single time points.
These methods preclude longitudinal studies of molecular targeting
of a compound in a tumor and resultant effects on disease progression
in the same animal. As a result, it is difficult to directly link pharmaco-
dynamics of a therapeutic agent in a tumor microenvironment to re-
duced tumor growth in vivo.
Our laboratory has developed imaging reporters to quantify acti-
vation of chemokine receptors in cell-based assays and living mice
[16,17]. We recently devised an imaging system based on Gaussia
luciferase protein fragment complementation to quantify ligand-receptor
binding, the initial step in chemokine receptor signaling [18]. We used
this optical imaging technology to show that intercellular binding be-
tween CXCL12 and CXCR4 occurs in a mouse model of disseminated
intraperitoneal ovarian cancer. We also established that treatment with
AMD3100, a clinically approved inhibitor of CXCL12-CXCR4,
blocked ligand-receptor binding in the tumor microenvironment of
mice with disseminated ovarian cancer. Furthermore, using separate
imaging reporters to monitor CXCL12-CXCR4 binding and tumor
growth, we demonstrated that single-agent therapy with AMD3100
blocked CXCL12-CXCR4 binding, reduced tumor growth, and mod-
estly prolonged survival of mice with disseminated ovarian cancer.
These results establish an in vivo imaging technology for pharmaco-
dynamics of CXCL12-CXCR4 inhibitors in preclinical drug develop-
ment and support clinical translation of compounds targeting this
chemokine receptor for treatment of women with ovarian cancer.
Materials and Methods
Cells
HeyA8 ovarian cancer cells (provided by Gordon Mills, MD
Anderson Cancer Center) were stably transduced with recombinant
lentiviruses for CXCL12 fused to the C-terminal fragment of Gaussia
luciferase (CXCL12-CG) or the N-terminal fragment of Gaussia
luciferase fused to CXCR4 (NG-CXCR4). We transduced HeyA8
cells with a secreted C-terminal fragment of Gaussia luciferase (CG).
NG-CXCR4 cells also were transduced with firefly luciferase [19].
Batch populations of cells were used for all experiments. Cells were
cultured in Dulbecco modified Eagle medium (Invitrogen, Carlsbad, CA),
10% fetal bovine serum, 1% glutamine, and 0.1% penicillin/streptomycin/
gentamicin. Cells were grown in a 37°C incubator with 5% CO2.
Reverse Transcription–Polymerase Chain Reaction
and Quantitative Reverse Transcription–Polymerase
Chain Reaction
RNA was extracted from cells using TRIzol reagent according to the
manufacturer’s directions. Expression of CXCL12-α in HeyA8 cells
was determined by reverse transcription–polymerase chain reaction
(RT-PCR) using primers 5′-TGAGCAGTGAATGATTCAGTGTT-
3′ and 5′-CTTCTCCTGGACCATTTTCACAT-3′. Messenger RNA
for CXCL12-CG or CG in stably transduced HeyA8 cells was quanti-
fied using primers for CG: 5′-GGCGATCGTCGACATTCCTG-3′
and 5′-GTCACCACCGGCCCCCTTG-3′. Primers for glyceral-
dehyde phosphate dehydrogenase were 5′-GAAGGTGAAGGTCG-
GAGT-3′ and 5′-GAAGATGGTGATGGGATTTC-3′. Samples for
quantitative RT-PCR were analyzed on an Eppendorf RealPlex
QRT-PCR instrument using SYBR Green detection. Amounts of mes-
senger RNA for CXCL12-CG and CG were normalized to glyceral-
dehyde phosphate dehydrogenase and expressed as ΔΔC t values.
Flow Cytometry
Cells were stained with an antibody to CXCR4 (clone 12G5; R&D
Systems, Minneapolis, MN) or matched isotype control as described
previously [20].
Western Blot Analysis
Cells were cultured in serum-free medium overnight and then
stimulated for 10 minutes with various concentrations of recombinant
CXCL12-α (R&D Systems). Cell lysates were blotted for phosphory-
lated AKT (Cell Signaling, Danvers, MA) as described previously [21].
Blots were stripped and reprobed for total AKT as a loading control.
Coculture Experiments
NG-CXCR4 cells were coseeded with either CXCL12-CG or CG
cells in black-walled 96-well plates (1 × 104 cells of each type). Cells were
plated in standard culture medium and then switched the following day
to phenol red–free Dulbecco modified Eagle medium (Invitrogen) with-
out serum for assays. In selected experiments, cells were incubated with
AMD3100 to inhibit CXCL12 binding to CXCR4 (Tocris, Ellisville,
MO), small molecule inhibitors of CXCR7 (gift of ChemoCentryx,
Mountain View, CA), or vehicle control for AMD3100 (phosphate-
buffered saline [PBS]) at concentrations listed in figure legends. Biolumi-
nescence from Gaussia luciferase complementation was measured as
described previously and normalized to total protein per well quan-
tified by sulforhodamine B staining [21].
Animal Studies
All animal procedures were approved by the University of Michigan
Committee for the Use and Care of Animals. A total of 1.25 to 2.5 ×
105 NG-CXCR4 cells were injected with an equal number of
CXCL12-CG or CG cells intraperitoneally in 100 μl of 0.9% NaCl
into 5- to 7-week-old female NcrNu/Nu (Harlan, Indianapolis, IN) or
NOD/SCID IL2rγ−/− female mice (Taconic, Hudson, NY) [22]. To in-
hibit CXCL12 binding to CXCR4, we treated mice with AMD3100
administered either as 1.25 mg/kg i.p. injections twice per day or as
14-day 0.5-μl/h osmotic pumps (Alzet, Cupertino, CA) loaded with
25 mg/ml AMD3100. Control mice received injections or pumps with
0.9% NaCl. Pumps were implanted 10 days after injection of ovarian
cancer cells.
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Animal Imaging Studies
Bioluminescence imaging was performed on an IVIS Spectrum
(Caliper, Hopkinton, MA). For Gaussia luciferase imaging, mice were in-
jected intravenously through tail vein with 4 mg/kg coelenterazine [23].
Mice were imaged immediately after injection using 3-minute acquisition
and large binning. Firefly luciferase imaging was performed as described
previously [24]. Data were quantified as photon flux with Living
Image software (Caliper) to account for differences in image acquisition
time for firefly luciferase imaging.
Statistics
Graphs and statistical analyses were prepared with GraphPad
Prism (GraphPad Software, La Jolla, CA). Cell culture studies were per-
formed three to five times, whereas animal studies were performed two
to three times. Data were plotted as mean values with SEM. Pairs of
data were analyzed by Mann-Whitney U test to determine statistically
significant differences. Kaplan-Meier survival curves were analyzed by
Gehan-Breslow-Wilcoxon test.
Results
HeyA8 Cells Activate CXCL12-CXCR4 Signaling
Chemokine receptor CXCR4 is expressed by several ovarian cancer
cell lines and approximately 60% of metastatic human ovarian cancers
[8,25]. We used flow cytometry to analyze cell surface expression of
CXCR4 on HeyA8 ovarian cancer cells. These cells express modest
levels of CXCR4 (Figure 1A). HeyA8 cells also activate AKT, a known
downstream effector of CXCR4 signaling, in response to CXCL12
(Figure 1B). HeyA8 cells do not express detectable CXCL12 as determined
by RT-PCR. These results establish that HeyA8 ovarian cancer cells
have intact CXCL12-CXCR4 signaling, validating them as an appropriate
model for imaging studies of CXCL12-CXCR4 binding and function.
Gaussia Luciferase Complementation Detects
CXCL12-CXCR4 Binding in Cell-Based Assays
We recently described a protein fragment complementation sys-
tem using Gaussia luciferase to quantify chemokine binding to target
receptors [18]. In this system, N- and C-terminal fragments of Gaussia
luciferase are fused to the extracellular N-terminus of CXCR4 and
the C-terminus of CXCL12 (NG-CXCR4 and CXCL12-CG, respec-
tively; Figure 2A). These orientations of fusion proteins maximize bio-
luminescence from CXCL12 binding to CXCR4 [18]. Binding of
CXCL12-CG to NG-CXCR4 brings together luciferase fragments to
produce light as a quantitative measure of ligand-receptor binding. Be-
cause Gaussia luciferase complementation is fully reversible, dissocia-
tion of CXCL12 from CXCR4 turns off bioluminescence [26]. NG
and CG fragments are positioned to detect ligand binding in the extra-
cellular space and in intracellular compartments, using advantages of
Gaussia luciferase as an ATP-independent enzyme with broad pH
optimum [23].
We transduced HeyA8 cells with lentiviral vectors to generate
stable populations of cells secreting CXCL12-CG or expressing NG-
CXCR4, respectively. As a control for bioluminescence from nonspe-
cific association of NG and CG fragments alone, we also established
populations of cells that secrete an unfused CG fragment. HeyA8-
NG-CXCR4 cells expressed modestly higher levels of CXCR4 on the
cell surface than parental HeyA8 cells (Figure 2B). HeyA8-CXCL12-
CG and HeyA8-CG cells expressed comparable levels of CG by QRT-
PCR (data not shown).
To establish that Gaussia luciferase complementation could quantify
intercellular CXCL12-CXCR4 binding in ovarian cancer cells, we co-
cultured HeyA8-NG-CXCR4 cells with equal numbers of HeyA8 cells
secreting either CXCL12-CG or CG. After 2 hours of coculture, bio-
luminescence from CXCL12-CG binding to NG-CXCR4 was about
eight-fold greater than nonspecific association of secreted CGwith NG-
CXCR4 (P < .01; Figure 2C). We also measured changes in biolumi-
nescence over time in this coculture model. Bioluminescence from
CXCL12-CG binding to NG-CXCR4 was significantly greater than
control signal (CG and NG-CXCR4) within 15 minutes (P < .01;
Figure 2D). Signal from CXCL12-CG and NG-CXCR4 cocultures in-
creased over time, whereas minimal light from CG and NG-CXCR4
did not change for 2 hours. Collectively, these data demonstrate that
Gaussia luciferase complementation can detect CXCL12-CXCR4
binding in ovarian cancer cells.
Figure 1. HeyA8 ovarian cancer cells express functional CXCR4. (A) Cell surface levels of CXCR4 on HeyA8 cells were determined by
flow cytometry. Dark line indicates unstained; light line, isotype antibody control; and intermediate line, CXCR4 antibody. (B) HeyA8 cells
were serum starved overnight and then incubated with 2 or 100 ng/ml CXCL12 for 10 minutes. Cell lysates were probed for phosphor-
ylated AKT (p-AKT, active form) and total AKT as a control for protein loading.
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AMD3100 Blocks CXCL12-CXCR4 Complementation
in Intact Cells
To quantify inhibition of CXCL12 binding to CXCR4, we
treated cells with AMD3100, a clinically approved inhibitor of
CXCL12-CXCR4 [27]. We prepared cocultures of HeyA8 NG-
CXCR4 cells with equal numbers of HeyA8-CXCL12-CG or
HeyA8-CG cells. After allowing cells to adhere overnight, we
changed cells to medium containing 1 μM AMD3100 for various
periods through 4 hours. As a control, we incubated cells with
1 μM CCX771, a specific inhibitor of CXCL12 binding to CXCR7
[28]. Bioluminescence from CXCL12-CG binding to NG-CXCR4
decreased within 30 minutes of treatment with AMD3100 (P < .01;
Figure 3A). Signal decreased progressively over time to≈50% of initial
bioluminescence by 4 hours (P < .01). By comparison, AMD3100 did
not alter background signal from secreted CG and NG-CXCR4, and
incubation with CCX771 had no effect on bioluminescence produced
by CXCL12-CG/NG-CXCR4 or the control pair of CG/NG-
CXCR4. Treatment with 1 μMAMD3100 also decreased biolumines-
cence from CXCL12-CG binding to NG-CXCR4 relative to cocultures
of these cells treated with PBS vehicle control (Figure W1).
Treatment with AMD3100 for 2 hours also produced dose-dependent
inhibition of complementation between CXCL12-CG and NG-CXCR4
(Figure 3B). We observed a significant decrease in bioluminescence with
10 nM AMD3100, and maximum inhibition occurred with 100 nM
of this drug (P < .05 and P < .01, respectively). The EC50 for inhibiting
bioluminescence from CXCL12-CG binding to NG-CXCR4 was
≈30 nM AMD3100, which is comparable to the≈20 nMEC50 value
reported previously for inhibiting binding of recombinant CXCL12
to CXCR4 at 4°C [29]. The CXCR7 inhibitor CCX771 did not
affect bioluminescence from CXCL12-CG and NG-CXCR4. Neither
AMD3100 nor CCX771 changed the low-level signal from secreted
CG and NG-CXCR4.
We also tested to what extent AMD3100 inhibits a preexisting com-
plementation signal from CXCL12-CG binding to NG-CXCR4,
Figure 2. Gaussia luciferase complementation detects CXCL12-CXCR4 binding in cell-based assays. (A) Schematic diagram of comple-
mentation system. The C-terminus of CXCL12 is fused to the C-terminal fragment of Gaussia luciferase (CXCL12-CG), and the N-terminal
fragment of Gaussia is fused to the extracellular N-terminus of CXCR4 (NG-CXCR4). These orientations of fusion proteins position NG
and CG fragments in the extracellular space. CXCL12 binding to CXCR4 brings together NG and CG enzyme fragments, reconstituting an
active enzyme to produce light. (B) Flow cytometry shows expression of CXCR4 on the surface of NG-CXCR4 cells. Dark line indicates
unstained; light line, isotype antibody control; and intermediate line, CXCR4 antibody. (C) HeyA8-NG-CXCR4 cells were cocultured with
equal numbers of HeyA8-CXCL12-CG (CXCL12-CG/NG-CXCR4) or control cells secreting unfused CG (CG/NG-CXCR4) for 2 hours before
quantifying Gaussia luciferase bioluminescence. Photon flux was normalized to relative amounts of total protein per well, and data were
expressed as mean values ± SEM for each coculture (n = 4 per condition). (D) Cocultures of HeyA8-CXCL12-CG/NG-CXCR4 or HeyA8-
CG/NG-CXCR4 cells were incubated for various periods through 2 hours before quantifying Gaussia luciferase bioluminescence as
described in C (n = 4 per condition). **P < .01. ***P < .005.
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which more closely models use of AMD3100 to treat ovarian cancer.
We incubated cocultures of HeyA8-CXCL12-CG/HeyA8-NG-
CXCR4 cells and HeyA8-CG/NG-CXCR4 cells for 4 hours and then
added increasing concentrations of AMD3100 for an additional 4 hours.
Under these conditions, we again observed a significant decrease in bio-
luminescence from 10 nM AMD3100, although the EC50 for inhibiting
established ligand-receptor binding increased to ≈200 nM (P < .05;
Figure 3C ). The increase in EC50 likely is due to the inability of
AMD3100 to disrupt CXCL12-CXCR4 complexes that formed and
internalized before adding drug.
Imaging CXCL12-CXCR4 Complementation in a
Mouse Model of Ovarian Cancer
To image CXCL12 binding to CXCR4 in vivo, we injected
HeyA8-NG-CXCR4 cells with either HeyA8-CXCL12-CG or
HeyA8-CG cells intraperitoneally into nude mice. This model repro-
duces intraperitoneal metastasis of ovarian cancer, which is the principal
site of disease in patients. HeyA8-NG-CXCR4 cells also stably ex-
pressed firefly luciferase, an enzyme that uses a different substrate than
Gaussia luciferase. Bioluminescence imaging for firefly luciferase pro-
vides a noninvasive measure of relative numbers of these cells in the
peritoneal cavity independent of Gaussia luciferase complementation.
Gaussia luciferase imaging in mice injected with HeyA8-CXCL12-
CG and HeyA8-NG-CXCR4 cells showed bioluminescence from
CXCL12 binding to CXCR4 in multiple sites throughout the abdomen
(Figure 4A). Signal from CXCL12-CG and NG-CXCR4 was ≈15-
fold greater than the control pair of CG and NG-CXCR4, the latter
of which was nearly at background levels (P < .01; Figure 4B). Firefly
luciferase imaging revealed diffuse signal from HeyA8-NG-CXCR4
cells in both groups of mice, establishing that disseminated disease
had developed in both cohorts of animals. After mice were killed, we
observedmultiple tumor masses disseminated throughout the abdomen
(data not shown). In these and other in vivo images, we note that bio-
luminescence fromGaussia luciferase does not strictly coincide with firefly
luciferase. Such differences likely result from relatively greater attenuation
of signal from Gaussia luciferase, which emits light at 480 nm as com-
pared with peak emission of firefly luciferase at 560 nm. In addition,
Gaussia luciferase bioluminescence only is produced at sites where
CXCL12-CG binds to NG-CXCR4, whereas NG-CXCR4 cells consti-
tutively express firefly luciferase independent of binding to CXCL12-CG.
To validate the complementation system for quantifying inhibition
of CXCL12-CXCR4 binding in vivo, we injected HeyA8-CXCL12-
CG and HeyA8-NG-CXCR4 intraperitoneally in mice. After ob-
taining baseline imaging for Gaussia luciferase complementation, we
treated groups of animals with AMD3100 or vehicle control for 3 days
and then repeated the imaging study.Mice treated with AMD3100 had
bioluminescence only slightly above baseline, which was similar to
the minimal signal produced by nonspecific association of CG and
Figure 3. AMD3100 inhibits bioluminescence from CXCL12-CXCR4 binding. (A) Cocultures of HeyA8 cells (CXCL12-CG/NG-CXCR4 or
CG/NG-CXCR4) were incubated for increasing periods with 1 μMAMD3100, a CXCR4 inhibitor, or CCX771, an inhibitor of CXCL12 binding
to CXCR7. Gaussia luciferase bioluminescence was quantified as described in Figure 2, and data were presented as mean values ± SEM
(n= 4 per condition). (B) Cocultures of CXCL12-CG/NG-CXCR4 or control CG/NG-CXCR4 cells were incubated for 2 hours with increasing
concentrations of AMD3100 or CCX771, respectively, before measuring bioluminescence from Gaussia luciferase (n = 4 per condition).
(C) Pairs of HeyA8 cells were incubated for 4 hours before adding increasing concentrations of AMD3100 for an additional 4 hours before
quantify bioluminescence (n = 4 per condition). *P < .05. **P < .01.
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NG-CXCR4 (Figure 5A; see Figure 4A). Treatment with AMD3100
reduced bioluminescence from CXCL12-CG binding to NG-CXCR4
below the pretreatment value, whereas continued tumor growth caused
Gaussia luciferase bioluminescence signal to increase in animals receiv-
ing vehicle control (P < .05; Figure 5B). By comparison, bioluminescence
from firefly luciferase increased in both groups of mice due to tumor
growth during 3 days (Figure 5, C and D). The increase in firefly lucif-
erase signal was slightly greater in mice treated with vehicle control,
although differences between groups were not significant at this time
point. Because AMD3100 suppressed Gaussia luciferase complementa-
tion below pretreatment levels while firefly luciferase signal increased,
these data indicate that loss of Gaussia bioluminescence is due to inhibi-
tion of CXCL12 binding to CXCR4 rather than general cell death.
Noninvasive Imaging of CXCR4-Targeted Therapy
in Living Mice
Having established the ability to noninvasively quantify CXCL12-
CXCR4 binding in vivo, we used this imaging system to monitor
response to targeted therapy. We injected 1.25 × 105 cells each of
HeyA8-CXCL12-CG and HeyA8-NG-CXCR4 cells intraperitoneally
to generate disseminated ovarian cancer. After allowing tumors to grow
for 10 days, we treated mice with either AMD3100 or vehicle control.
Because AMD3100 has a short (3-4 hours) serum half-life, we delivered
this drug or vehicle control through subcutaneous osmotic pumps to
maintain effective levels of compound during prolonged periods of
treatment. Bioluminescence imaging for Gaussia luciferase after 5 and
11 days of treatment showed significantly lower signal in mice treated
with AMD3100 compared with vehicle control (P < .05 and P < .01,
respectively; Figures 6A and W2). These imaging data established that
AMD3100 effectively inhibited CXCL12 binding to CXCR4 over the
course of treatment. We imaged firefly luciferase activity from HeyA8-
NG-CXCR4 cells to determine effects of treatment on tumor growth.
Mice treated with AMD3100 had significantly lower firefly luciferase
signal on days 5 and 11 of therapy, showing that this compound limited
growth of ovarian cancer cells in vivo (Figure 6, B and C ). Gaussia
luciferase complementation between CXCL12-CG and NG-CXCR4
also could be blocked by AMD3100 in HeyA8-CXCL12-CG/
HeyA8-NG-CXCR4 cells recovered from ascites, indicating that cells
did not become resistant during the period of therapy (Figure W3).
Furthermore, treatment with AMD3100 modestly extended overall
survival of mice relative to animals receiving vehicle control (Figure 6D;
P < .05). Using bioluminescence imaging to monitor pharmacody-
namics and effects of therapy, these data establish that targeted inhibition
of CXCL12-CXCR4 reduces tumor growth and modestly increases
survival of mice with ovarian cancer.
Discussion
Prognosis in ovarian cancer remains dismal because most patients pres-
ent with advanced disease with malignant cells disseminated through-
out the peritoneal space. To improve outcomes for these patients, there
is an unmet clinical need for new therapeutic strategies to limit growth of
ovarian cancer. Chemokine CXCL12 and its receptor CXCR4 seem to
be promising therapeutic targets in ovarian cancer. CXCL12-CXCR4
signaling is proposed to regulate metastasis of more than 20 different
cancers, including intraperitoneal dissemination of gastric cancer [30].
The expression of CXCR4 in ovarian cancer and levels of CXCL12 in
ascites both increase progressively with higher stages of disease, suggest-
ing that CXCL12-CXCR4 signaling may contribute to tumor growth
and dissemination [25,31]. Association of CXCL12-CXCR4 with me-
tastatic ovarian cancer is further strengthened by studies showing that
the tumor microenvironment upregulates this receptor, promoting pro-
liferation and invasion of ovarian cancer cells through the extracellular
Figure 4. Imaging CXCL12-CXCR4 binding in living mice with disseminated intraperitoneal ovarian cancer. (A) Pairs of HeyA8 ovarian
cancer cells (CG/NG-CXCR4) or (CXCL12-CG/NG-CXCR4) were injected intraperitoneally into mice (1.25 × 105 of each cell type per mouse).
Two weeks after injection, mice were imaged with coelenterazine to detect bioluminescence from Gaussia luciferase complementation in
cells with the interacting pair (CXCL12-CG/NG-CXCR4) or the control pair (CG/NG-CXCR4). Firefly luciferase images show relative numbers of
HeyA8-NG-CXCR4 cells, which constitutively express this imaging reporter. Scale bars for imaging data depict ranges of pseudocolors with
red and blue representing highest and lowest photon flux values, respectively. (B) Quantified data for Gaussia luciferase bioluminescence
(n = 5 per group). Data were graphed as mean values ± SEM. *P < .05.
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matrix [10,25,31]. Blocking CXCL12-CXCR4 signaling may limit
progression of ovarian cancer and provide a new therapeutic strategy
to prevent or more effectively treat advanced stage disease.
We used a new optical imaging reporter system based on Gaussia
luciferase complementation to quantify CXCL12 binding to CXCR4 in
the microenvironment of ovarian cancer. We previously demonstrated
that this complementation system could image CXCL12-CXCR4
binding in breast cancer cells that lack expression of endogenous
CXCR4 [18]. In the current study, we established that this imaging
system also generates robust signal using HeyA8 cells that normally ex-
press wild-type unfused CXCR4. Wild-type CXCR4 will bind
CXCL12-CG without generating light, serving as a competitor for
complementation between CXCL12-CG and NG-CXCR4. The abil-
ity to use Gaussia luciferase complementation to quantify CXCL12-
CXCR4 binding in cells with endogenous CXCR4 extends applications
of this imaging system to the large number of ovarian and other cancer
cells that express this receptor. Because Gaussia and firefly luciferases
use different substrates, we also were able to combine Gaussia luciferase
imaging for CXCL12-CXCR4 binding with firefly luciferase imaging
for tumor growth in vivo. Using this system, we established that treat-
ment with AMD3100, a clinically approved inhibitor of CXCL12
binding to CXCR4, blocked this ligand-receptor pair in cell-based
assays and living mice with disseminated ovarian cancer. Inhibiting
CXCL12 binding to CXCR4 decreased growth of ovarian cancer
cells and modestly prolonged survival of mice relative to animals
treated with vehicle control. Collectively, these data suggest that
Figure 5. AMD3100 blocks CXCL12-CXCR4 binding in vivo. (A) Mice were injected intraperitoneally with 2.5 × 105 each of HeyA8-
CXCL12-CG and NG-CXCR4 cells. Baseline images for Gaussia luciferase complementation and firefly luciferase expressed constitutively
by NG-CXCR4 cells were obtained 7 days after injecting ovarian cancer cells. Mice then were treated for 3 days with AMD3100 or vehicle
control before repeating imaging studies. Representative images for mice treated with AMD3100 or vehicle control are displayed. Scale
bars denote pseudocolor displays for bioluminescence for Gaussia and firefly luciferase images, respectively. (B) Quantified data for
Gaussia luciferase (GL) activity (n = 7-8 per group). Change in bioluminescence from posttreatment to pretreatment values was calcu-
lated for each mouse, and mean values ± SEM were presented. *P < .05.
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targeting CXCL12-CXCR4 may offer therapeutic benefits in ad-
vanced ovarian cancer.
Similar to our current research, a previous study by Kajiyama et al.
[32] showed that AMD3100 limited tumor dissemination and over-
all tumor burden in a mouse model of intraperitoneal ovarian cancer.
However, the previous study reported no effect of AMD3100 treat-
ment on overall survival. This disparity may be due to the use of
different cell lines and/or nude mice versus the more immunocom-
promised mouse strain we used. In addition, Kajiyama et al. injected
AMD3100 intraperitoneally for treatment studies, whereas we used
subcutaneous osmotic infusion pumps to deliver constant levels of
this drug. Chemotherapy for ovarian cancer typically is administered
intraperitoneally, but AMD3100 is cleared rapidly in vivo [33,34].
Whereas Gaussia luciferase complementation established that intra-
peritoneal delivery of AMD3100 can block CXCL12-CXCR4, we
used osmotic infusion pumps to achieve sustained inhibition of
ligand-receptor binding and maximize the ability to identify a sur-
vival benefit. CXCL12-CXCR4 inhibitors with improved pharma-
cokinetics will mitigate this problem. During the preparation of this
article, Righi et al. [35] also demonstrated that AMD3100 delivered
from an osmotic infusion pump reduced growth of ovarian cancer
cells and extended survival in an immunocompetent mouse model.
Collectively, these studies establish CXCL12-CXCR4 as a promis-
ing molecular target for ovarian cancer therapy and emphasize the
Figure 6. AMD3100 reduces tumor growth and prolongs survival of mice with metastatic ovarian cancer. (A) Mice were injected intra-
peritoneally with 1.25 × 105 cells each of HeyA8-CXCL12-CG and NG-CXCR4 cells. After 10 days of tumor growth, mice were imaged for
baseline Gaussia luciferase activity immediately before implantation of osmotic infusion pumps with AMD3100 or vehicle control. Repeat
imaging studies for Gaussia luciferase complementation were performed on days 5 and 11 of treatment. The fold change in Gaussia
luciferase bioluminescence relative to the pretreatment baseline value was determined for each mouse, and mean values for each group ±
SEMwere graphed. (B) Representative firefly luciferase images for relative numbers of HeyA8-NG-CXCR4 cells before and on days 5 and 11
of treatment with AMD3100 or vehicle control. Scale bar shows pseudocolor display for photon flux values on all images. (C) Quantified data
for tumor growth measured by firefly luciferase activity. Fold change in bioluminescence on days 5 and 11 of treatment was determined
relative to pretreatment values for eachmouse, and data were presented asmean values± SEM (n=8 per group). (D) Kaplan-Meier survival
curve for mice treated with AMD3100 or vehicle control. Black arrow denotes start of therapy. *P < .05. **P < .01.
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importance of imaging technologies to monitor effective inhibition
of this pathway in vivo.
The combination of Gaussia luciferase complementation reporters
for CXCL12-CXCR4 binding and firefly luciferase for tumor pro-
gression offers notable advantages for discovery and development
of new agents targeting this ligand-receptor pair. The HeyA8 ovarian
cancer cells can be used to quantify ligand-receptor binding in cell-
based, multiwell plate assays compatible with high-throughput
screening. These same reporter cells can then be used to test promising
lead compounds in preclinical animal models of ovarian cancer. The
complementation system provides the unique capability to quantify
pharmacodynamics of therapeutic compounds at the target site rather
than relying on serum levels of compound or inferring receptor inhibi-
tion in surrogate tissues. Inhibition of the target pathway then can be
correlated directly with effects on tumor growth in preclinical models.
Because the reporter constructs all are in lentiviral vectors, the imaging
reporters could be introduced readily into other cell lines and primary
ovarian cancer cells, establishing a panel of reporter cell types for cell-
based assays and animal models. A limitation of the existing HeyA8
reporter cells is that CXCL12-CG and NG-CXCR4 were expressed
by separate populations of cells, necessitating coculture or coimplanta-
tion of two different cell types. We tried coexpressing both reporters in
the same cell, but the magnitude of signal from CXCL12-CG binding
to NG-CXCR4 was notably lower (Luker KE, et al., unpublished data).
We are working to overcome this limitation.
In the current study, we analyzed effects of AMD3100 on mice
with established intraperitoneal ovarian cancer metastases. Although
this model reproduces the stage at which most patients present with
ovarian cancer, it bypasses steps of metastasis including invasion and
dissemination of malignant cells from the ovary and/or fallopian tube
into the peritoneum. Because cell culture studies demonstrate that
CXCL12-CXCR4 signaling promotes these processes, inhibitors of this
signaling pathway also may limit progression from localized disease.
Further testing with genetically engineered mouse models of ovarian
cancer or intraovarian injection of malignant cells will be required to
validate this hypothesis. We administered AMD3100 as a single thera-
peutic agent because of the challenges of managing toxicities in mice
treated with multiple compounds. In clinical practice, CXCL12-
CXCR4 inhibitors would almost certainly be used as part of integrated
therapy for ovarian cancer, including debulking surgery and combination
chemotherapy. Our findings support further development of CXCL12-
CXCR4 inhibitors for therapy for ovarian cancer and other malignancies
and translation of such agents to clinical trials in ovarian cancer.
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Figure W1. Cocultures of HeyA8-CXCL12-CG/NG-CXCR4 cells
were treated for increasing periods through 6 hours with 1 μM
AMD3100 or matched volume of PBS vehicle control. Parallel
cocultures of HeyA8-CG/NG-CXCR4 cells were incubated with
PBS vehicle control for the same periods. Photons from Gaussia
luciferase bioluminescence were quantified and normalized to
total protein per well. Data were presented as mean values ± SEM
(n = 4 per condition).
Figure W3. HeyA8-CXCL12-CG and NG-CXCR4 cells were recov-
ered from ascites of mice treated with AMD3100. Mixtures of cells
recovered from mice were treated for 2 hours with increasing con-
centrations of AMD3100 before quantifying bioluminescence from
Gaussia luciferase complementation (n = 4 per condition). Data
were normalized to relative amounts of total protein per well and
graphed as mean values ± SEM. **P < .01.
Figure W2. Representative bioluminescence images for Gaussia luciferase complementation between CXCL12-CG and NG-CXCR4 in
mice are shown before (pretreatment) and during treatment with AMD3100 or vehicle control. Images were obtained on days 5 and 11 of
treatment. Scale bar denotes range of pseudocolors used to depict photon flux for all images.
